Antioxidant or anti-inflammatory composition containing fermented cabbage as an active ingredient

A yeast-fermented cabbage composition, using Saccharomyces strains, enhances sulforaphane production and inhibits nitrite, addressing the limited research in this area and offering antioxidant and anti-inflammatory benefits for health, cosmetic, and pharmaceutical uses.

KR103046615B1Active Publication Date: 2026-11-11KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
KR1020230078610
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2023-02-28
Filing Date
2023-06-20
Publication Date
2026-11-11
Estimated Expiration
2043-06-20

AI Technical Summary

Technical Problem

Current research on yeast-fermented cabbage is limited, and there is a need for a composition that leverages its antioxidant and anti-inflammatory effects for health, cosmetic, and pharmaceutical applications.

Method used

A composition comprising fermented cabbage as an active ingredient, using specific strains of Saccharomyces yeast, such as Saccharomyces cerevisiae, and optimized fermentation conditions to enhance sulforaphane production and inhibit nitrite generation, suitable for health functional foods, cosmetics, and pharmaceuticals.

Benefits of technology

The composition exhibits significant antioxidant and anti-inflammatory effects, providing benefits for preventing or treating diseases caused by oxidative stress and inflammation, and improving skin health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023067412032-PAT00002_ABST
    Figure 112023067412032-PAT00002_ABST
Patent Text Reader

Abstract

The present invention relates to an antioxidant or anti-inflammatory composition comprising fermented cabbage as an active ingredient. By using eight types of yeast, Saccharomyces cerevisiae yeast was identified as the yeast that ferments most effectively. Since cabbage fermented with Saccharomyces cerevisiae yeast exhibits antioxidant or anti-inflammatory effects, it can be usefully utilized in health functional food compositions, cosmetic compositions, and pharmaceutical compositions for antioxidant or anti-inflammatory purposes. This research is the result of a study conducted with support from the Ministry of SMEs and Startups and the Korea Technology Information Promotion Agency for SMEs under the “Regional Specialized Industry Development+ (R&D, S3273067)” project.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to an antioxidant or anti-inflammatory composition comprising fermented cabbage as an active ingredient. Background Technology

[0003] cabbage( Brassica oleracea var. capitata Cabbage belongs to the Cruciferous family along with broccoli and cauliflower, and as one of the oldest cultivated crops, it is considered a longevity food. Cabbage is beneficial to health as a source of fiber, vitamins, polyphenols, flavonoids, and glucosinolates. Glucosinolates are in an inactive state and are broken down by myrosinase within the vegetable during processing; the resulting substances exhibit physiological activity within the human body, and among these physiologically active substances is sulforaphane, which has antioxidant and anticancer effects.

[0004] Yeast is the most common microorganism used in industrial applications and plays a crucial role in the production of food, biofuels, and various bioproducts. Since the beta-glucans and mannan oligosaccharides in yeast cell walls increase phagocytosis and cytokine production, yeast is a potential immunomodulator.

[0005] Sauerkraut is a representative fermented cabbage food currently sold on the market, and it is a product made through lactic acid fermentation. Recently, the antioxidant and anti-inflammatory effects of fermented cabbage extracts using lactic acid bacteria are being studied.

[0006] However, research on yeast-fermented cabbage is currently limited. Accordingly, in this invention, the physicochemical characteristics of cabbage resulting from fermentation were investigated to identify a yeast suitable for cabbage fermentation, and the increase in sulforaphane and antioxidant activity, as well as anti-inflammatory effects resulting from fermentation, were confirmed, thereby establishing this invention. Prior art literature

[0008] Korean Patent Publication No. 10-1992336 (June 18, 2019) The problem to be solved

[0009] The objective of the present invention is to provide an antioxidant or anti-inflammatory composition comprising fermented cabbage as an active ingredient. means of solving the problem

[0011] To achieve the above objectives, the present invention provides a health functional food composition for antioxidant or anti-inflammatory purposes comprising fermented cabbage as an active ingredient.

[0012] In one embodiment of the present invention, the fermentation strain of the cabbage fermentation product may be a strain of the genus Saccharomyces, but is not limited thereto.

[0013] In one embodiment of the present invention, the genus Saccharomyces strain is Saccharomyces cerevisiae ( Saccharomyces cerevisiae ), Saccharomyces yubarum( Saccharomyces uqvarum ), Saccharomyces Ellipsoideus( Saccharomyces ellipsoideus ), Saccharomyces carlsbergensis( Saccharomyces carlsbergensis ), Saccharomyces sake( Saccharomyces sake ), Saccharomyces Coreanus( Saccharomyces coreanus ), Saccharomyces repolitica( Saccharomyces lipolytica ) Saccharomyces boulardii( Saccharomyces boulardii ) or Saccharomyces Pastorianus( Saccharomyces pastorianus ), preferably Saccharomyces cerevisiae ( Saccharomyces cerevisiae It may be one or more strains selected from the group consisting of ), preferably Saccharomyces cerevisiae ( Saccharomyces cerevisiae It could be ).

[0014] In one embodiment of the present invention, the cabbage fermentation product may be prepared by mixing cabbage and distilled water in a weight ratio of 1:7 to 13 and fermenting, but is not limited thereto.

[0015] In one embodiment of the present invention, the fermentation may be performed at 15 to 45 ℃ at 200 to 300 rpm for 20 to 28 hours, but is not limited thereto.

[0016] In one embodiment of the present invention, the cabbage fermentation product may promote the production of sulforaphane, but is not limited thereto.

[0017] In one embodiment of the present invention, the cabbage fermentation product may inhibit the generation of nitrite, but is not limited thereto.

[0018] In one embodiment of the present invention, the cabbage fermentation product may inhibit inducible nitric oxide synthetase (iNOS) activity, but is not limited thereto.

[0019] In addition, the present invention provides a cosmetic composition for antioxidant or anti-inflammatory purposes comprising a fermented cabbage extract as an active ingredient.

[0020] Finally, the present invention provides a pharmaceutical composition for the prevention or treatment of diseases caused by oxidative stress or inflammatory diseases, comprising a fermented cabbage extract as an active ingredient.

[0021] In one embodiment of the present invention, the disease caused by oxidative stress may be one or more selected from the group consisting of arteriosclerosis, heart failure, hypertensive heart disease, arrhythmia, myocardial infarction, hyperlipidemia, skin aging, immune disease and cancer, but is not limited thereto.

[0022] In one embodiment of the present invention, the inflammatory disease may be one or more selected from the group consisting of inflammatory bowel disease, inflammatory collagen vascular disease, glomerulonephritis, inflammatory skin disease, sarcoidosis, retinitis, gastritis, hepatitis, enteritis, arthritis, tonsillitis, pharyngitis, bronchitis, pneumonia, pancreatitis, sepsis, cystitis, nephritis, and neuritis, but is not limited thereto. Effects of the invention

[0024] According to the antioxidant or anti-inflammatory composition containing cabbage fermentation product of the present invention, using eight types of yeast, yeast with excellent fermentation Saccharomyces cerevisiae They discovered yeast, Saccharomyces cerevisiae Cabbage fermented with yeast has antioxidant or anti-inflammatory effects, so it can be usefully used in health functional food compositions, cosmetic compositions, and pharmaceutical compositions. Brief explanation of the drawing

[0026] Figure 1 is a figure showing the change in the number of viable yeast cells in a 10% cabbage fermented product in one embodiment of the present invention. FIG. 2 is a figure showing the correlation between the water-soluble solid content and pH or viable cell count of a cabbage fermented by eight types of yeast in one embodiment of the present invention. FIG. 3 is a figure showing the fermentation profile of eight types of yeast in one embodiment of the present invention. Figure 4 is a figure showing the results of confirming the cytotoxicity of a fermented cabbage product in one embodiment of the present invention. Figure 5 is a figure showing the results of confirming the antioxidant activity of a fermented cabbage product in one embodiment of the present invention. Figure 6 is a figure showing the results of confirming the ROS generation inhibitory effect of cabbage fermentation product in one embodiment of the present invention. Figure 7 is a figure showing the results of confirming the production of nitrite in a fermented cabbage product in one embodiment of the present invention. FIG. 8 is a figure showing the results of confirming the protein expression of a fermented cabbage product in one embodiment of the present invention. Specific details for implementing the invention

[0027] Hereinafter, the present invention will be described in detail with reference to the attached drawings for embodiments of the present invention. However, the following embodiments are presented as examples of the present invention, and if it is determined that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the essence of the present invention, such detailed description may be omitted, and the present invention is not limited by this. The present invention is capable of various modifications and applications within the scope of the claims set forth below and the equivalent scope interpreted therefrom.

[0028] Furthermore, the terminology used in this specification is used to appropriately describe preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs. Accordingly, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as “comprising” a certain component, unless specifically stated otherwise, this means that it does not exclude other components but may include additional components.

[0029] Throughout this specification, '%' used to indicate the concentration of a particular substance is (w / w) % for solid / solid, (w / v) % for solid / liquid, and (v / v) % for liquid / liquid, unless otherwise noted.

[0031] In one aspect, a health functional food composition for antioxidant or anti-inflammatory purposes is provided, comprising fermented cabbage as an active ingredient.

[0032] In one embodiment of the present invention, the fermentation strain of the cabbage fermentation product may be a strain of the genus Saccharomyces, but is not limited thereto.

[0033] In one embodiment of the present invention, the genus Saccharomyces strain is Saccharomyces cerevisiae ( Saccharomyces cerevisiae ), Saccharomyces yubarum( Saccharomyces uqvarum ), Saccharomyces Ellipsoideus( Saccharomyces ellipsoideus ), Saccharomyces carlsbergensis( Saccharomyces carlsbergensis ), Saccharomyces sake( Saccharomyces sake ), Saccharomyces Coreanus( Saccharomyces coreanus ), Saccharomyces repolitica( Saccharomyces lipolytica ) Saccharomyces boulardii( Saccharomyces boulardii ) and Saccharomyces Pastorianus( Saccharomyces pastorianus It may be one or more strains selected from the group consisting of ), preferably Saccharomyces cerevisiae ( Saccharomyces cerevisiae ), more preferably Saccharomyces cerevisiae It could be EC-1118.

[0034] In one embodiment of the present invention, the cabbage fermentation product may be prepared by mixing cabbage powder and distilled water in a weight ratio of 1:7 to 13, preferably 1:9 to 11, more preferably 1:9.5 to 10.5, and fermenting, but is not limited thereto.

[0035] In one embodiment of the present invention, the fermentation may be performed at 15 to 45°C, preferably 20 to 40°C, more preferably 25 to 35°C, at 200 to 300 rpm, preferably 230 to 270 rpm, more preferably 245 to 255 rpm for 20 to 28 hours, preferably 22 to 26 hours, more preferably 23 to 25 hours, but is not limited thereto.

[0036] In one embodiment of the present invention, the cabbage fermentation product may promote the production of sulforaphane, but is not limited thereto.

[0037] In one embodiment of the present invention, the cabbage fermentation product may inhibit the generation of nitrite, but is not limited thereto.

[0038] In one embodiment of the present invention, the cabbage fermentation product may inhibit inducible nitric oxide synthetase (iNOS) activity, but is not limited thereto.

[0039] The term “inducible nitric oxide synthetase (iNOS)” used in this invention is an enzyme that is induced by infection or pro-inflammatory stimuli in various cells and is most easily observed in macrophages and monocytes of patients with inflammation-related diseases. iNOS is a very important target for the treatment of chronic inflammatory diseases.

[0040] In addition to containing fermented cabbage as an active ingredient, the health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates, etc., as additional ingredients, as in conventional food compositions.

[0041] Examples of the natural carbohydrates described above include monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; polysaccharides, e.g., dextrin, cyclodextrin, etc., and conventional sugars, and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The flavoring agents described above may advantageously use natural flavoring agents (taumatin), fermented stevia cabbage extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.). The food composition of the present invention may be formulated in the same manner as the pharmaceutical composition described above and used as a functional food or added to various foods. Foods to which the composition of the present invention may be added include, for example, beverages, meat, chocolate, food products, confectionery, pizza, ramen, other noodles, chewing gum, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplements.

[0042] In addition, the above-mentioned health functional food composition may contain, in addition to the active ingredient fermented cabbage, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, the food composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages.

[0043] The health functional food composition of the present invention may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. In the present invention, the term "health functional food composition" refers to a food manufactured and processed using raw materials or ingredients having functional properties useful to the human body pursuant to Article 6727 of the Health Functional Foods Act, and means consuming it for the purpose of obtaining effects useful for health uses, such as regulating nutrients or physiological actions regarding the structure and function of the human body. The health functional food of the present invention may include conventional food additives, and unless otherwise stipulated, suitability as a food additive is determined according to the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the Food Additives Codex approved by the Ministry of Food and Drug Safety. Items listed in the aforementioned "Food Additives Codex" include, for example, chemically synthesized compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamon acid; and natural additives such as persimmon dye, fermented licorice and cabbage extract, crystalline cellulose, sorghum dye, and guar gum. Examples include mixed preparations such as L-sodium glutamate preparations, alkaline additives for noodles, preservative preparations, and tar dye preparations. For instance, a health functional food in tablet form may be produced by granulating a mixture of the active ingredient of the present invention with excipients, binders, disintegrants, and other additives using a conventional method, and then compression molding by adding a lubricant, etc., or by directly compression molding the mixture. Additionally, the health functional food in tablet form may contain a binder, etc., as necessary. Among health functional foods in capsule form, hard capsules may be manufactured by filling a conventional hard capsule with a mixture of the active ingredient of the present invention mixed with additives such as excipients, and soft capsules may be manufactured by filling a capsule base such as gelatin with a mixture of the active ingredient of the present invention mixed with additives such as excipients. The soft capsules may contain plasticizers such as glycerin or sorbitol, coloring agents, preservatives, etc., as necessary.A health functional food in the form of a pill can be prepared by molding a mixture of the active ingredient of the present invention, excipients, binders, disintegrants, etc., using a previously known method, and if necessary, it can be coated with sucrose or other coating agents, or the surface can be coated with a substance such as starch or talc. A health functional food in the form of a granule can be prepared by making a mixture of the active ingredient of the present invention, excipients, binders, disintegrants, etc., into a granular form using a previously known method, and may contain flavoring agents, stimulating agents, etc., if necessary.

[0045] In one aspect, the present invention provides a cosmetic composition for antioxidant or anti-inflammatory purposes comprising a fermented cabbage extract as an active ingredient.

[0046] The composition containing the fermented cabbage of the present invention can be used in various ways, such as for the prevention or improvement of skin diseases caused by antibiotic-resistant bacteria. Products to which the present composition can be added include, for example, cosmetics such as various creams, lotions, skin toners, and essences, as well as shampoos, rinses, cleansers, facial cleansers, soaps, treatments, packs, and beauty solutions.

[0047] The cosmetic composition of the present invention comprises a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, high molecular weight polysaccharides, sphingolipids, and seaweed extracts.

[0048] As for water-soluble vitamins, any that can be incorporated into cosmetics may be used, but preferably, examples include vitamin B1, vitamin B2, vitamin B6, pyridoxine, pyridoxine hydrochloride, vitamin B12, pantothenic acid, nicotinic acid, nicotinamide, folic acid, vitamin C, vitamin H, etc., and their salts (thiamine hydrochloride, sodium ascorbate, etc.) or derivatives (sodium ascorbate-2-phosphate, magnesium ascorbate-2-phosphate, etc.) are also included in the water-soluble vitamins that can be used in the present invention. Water-soluble vitamins can be obtained by conventional methods such as microbial conversion methods, purification methods from microbial cultures, enzymatic methods, or chemical synthesis methods.

[0049] As for the useful vitamin, any that can be incorporated into cosmetics may be used, but preferably, examples include vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (d1-alpha tocopherol, d-alpha tocopherol, d-alpha tocopherol), and their derivatives (ascorbin palmitate, ascorbin stearate, ascorbin dipalmitate, dl-alpha tocopherol acetate, dl-alpha tocopherol nicotinate, vitamin E, DL-pantotenyl alcohol, D-pantotenyl alcohol, pantotenyl ethyl ether, etc.) are also included in the useful vitamin used in the present invention. The useful vitamin can be obtained by conventional methods such as microbial conversion, purification from microbial cultures, enzymes, or chemical synthesis.

[0050] As for the high molecular weight peptide, any material that can be incorporated into cosmetics may be used, but preferably, collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, keratin, etc. The high molecular weight peptide can be obtained by purification through conventional methods such as purification from a microbial culture medium, enzymatic methods, or chemical synthesis methods, or it can be used by purifying it from natural materials such as the dermis of pigs or cattle, or silk fibers of silkworms.

[0051] As for the high molecular weight polysaccharide, any that can be incorporated into cosmetics may be used, but preferably, hydroxyethylcellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or its salt (sodium salt, etc.) may be used. For example, chondroitin sulfate or its salt, etc., can be used after purifying it from mammals or fish.

[0052] As for sphingolipids, any that can be incorporated into cosmetics may be used, but preferably, ceramides, phytosphingosines, sphingoglycolipids, etc. Sphingolipids can be obtained by purifying them by conventional methods or by chemical synthesis from mammals, fish, shellfish, yeast, or plants.

[0053] Any seaweed extract that can be incorporated into cosmetics may be used, but preferably, brown algae extract, red algae extract, green algae extract, etc., may be used. Additionally, calagenan, arginic acid, sodium alginate, potassium alginate, etc., purified from these seaweed extracts are also included in the seaweed extract used in the present invention. The seaweed extract can be obtained by purifying seaweed by conventional methods.

[0054] In addition to the essential ingredients mentioned above, the cosmetic composition of the present invention may also include other ingredients that are conventionally incorporated into cosmetic compositions as needed. Other ingredients that may be added include oil components, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, disinfectants, antioxidants, plant extracts, pH adjusters, alcohols, colorants, fragrances, blood circulation promoters, cooling agents, antiperspirants, purified water, etc. Examples of oil components include ester-based oils, hydrocarbon-based oils, silicone-based oils, fluorinated-based oils, animal oils, plant oils, etc.

[0055] As ester-based oils, tri-2-ethylhexanoate glyceryl, 2-ethylhexanoate cetyl, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, isocetyl isostearate, butyl stearate, ethyl linoleate, isopropyl linoleate, ethyl oleate, isocetyl myristate, isostearyl myristate, isostearyl palmitate, octyldodecyl myristate, isocetyl isostearate, diethyl sebacate, diisopropyl adipice, isoalkyl neopentanoate, tri(capryl, capric acid)glyceryl, tri-2-ethylhexanoate trimethylolpropane, triisostearate trimethylolpropane, tetra-2-ethylhexanoate pentaelislitol, cetyl caprylate, decyl lauricate, Hexyl laurate, Decyl myristate, Myristyl myristate, Cetyl myristate, Stearyl stearate, Decyl oleate, Cetyl lisinooleate, Isostearyl laurate, Isotridecyl myristate, Isocetyl palmitate, Octyl stearate, Isocetyl stearate, Isodecyl oleate, Octyldodecyl oleate, Octyldodecyl linoleate, Isopropyl isostearate, Cetostearyl 2-ethylhexanoate, Stearyl 2-ethylhexanoate, Hexyl isostearate, Ethylene glycol dioctanoate, Ethylene glycol dioleate, Propylene glycol dicaprine, Di(Capryl, Capric acid)propylene glycol, Propylene glycol dicaprylate, Neopentyl glycol dicaprine, Neopentyl glycol dioctanoate, Glyceryl tricaprylate, Glyceryl triundecylate, Glyceryl triisopalmitate, Glyceryl triisostearate, Octyldodecyl neopentanoate, Isostearyl octanoate, Octyl isononanoate, Hexyldecyl neodecanoate, Octyldodecyl neodecanoate, Isocetyl isostearate, Isostearyl isostearate, Octyldecyl isostearate, Polyglycerin oleic acid ester, Polyglycerin isostearic acid ester, Triisocetyl citrate, Triisoalkyl citrate, Triisooctyl citrate, Lauryl lactate, Myristyl lactate, Cetyl lactate, Octyldecyl lactate, Triethyl citrate, Acetyltriethyl citrate, Acetyltributyl citrate, Trioctyl citrate, Diisostearyl malate, Hydroxystearic acid 2-ethylhexyl, di2-ethylhexyl succinate, diisobutyl adipicate, diisopropyl sebacicate,Examples include ester systems such as dioctyl sebacate, cholesteryl stearate, cholesteryl isostearate, cholesteryl hydroxystearate, cholesteryl oleate, dihydrocholesteryl oleate, pitsteryl isostearate, pitsteryl oleate, isocetyl 12-stealloylhydroxystearate, stearyl 12-stealloylhydroxystearate, and isostearyl 12-stealloylhydroxystearate.

[0056] Examples of hydrocarbon oils include squalene, liquid paraffin, alpha-olefin oligomer, isoparaffin, ceresin, paraffin, liquid isoparaffin, polybutene, microcrystalline wax, and Vaseline.

[0057] Examples of silicone-based oils include polymethylsilicon, methylphenylsilicon, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, dimethylsiloxane and methylcetyloxysiloxane copolymer, dimethylsiloxane and methylstealoxysiloxane copolymer, alkyl-modified silicone oil, amino-modified silicone oil, etc.

[0058] Examples of fluorinated oils include perfluoropolyethers.

[0059] Examples of animal or plant oils include avocado oil, almond oil, olive oil, sesame oil, rice bran oil, safflower oil, soybean oil, corn oil, rapeseed oil, apricot kernel oil, palm kernel oil, palm oil, castor oil, sunflower oil, grapeseed oil, cottonseed oil, coconut oil, cucurbit oil, wheat germ oil, rice germ oil, shea butter, laurel oil, macadamia nut oil, meadowsweet oil, egg yolk oil, beef tallow, horse oil, mink oil, orange raffia oil, jojoba oil, candelilla wax, carnaba wax, liquid lanolin, hydrogenated castor oil, etc.

[0060] Examples of moisturizers include water-soluble low-molecular-weight moisturizers, oil-soluble molecular moisturizers, water-soluble polymers, and oil-soluble polymers.

[0061] Examples of water-soluble low molecular weight moisturizers include serine, glutamine, sorbitol, mannitol, pyrrolidone-sodium carboxylate, glycerin, propylene glycol, 1,3-butylene glycol, ethylene glycol, polyethylene glycol B (degree of polymerization n = 2 or more), polypropylene glycol (degree of polymerization n = 2 or more), polyglycerin B (degree of polymerization n = 2 or more), lactic acid, lactate, etc.

[0062] Examples of fat-soluble low-molecular-weight moisturizers include cholesterol and cholesterol esters.

[0063] Examples of water-soluble polymers include carboxyvinyl polymer, polyaspartate, tragacanth, xanthan gum, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, water-soluble chitin, chitosan, dextrin, etc.

[0064] Examples of fat-soluble polymers include polyvinylpyrrolidone and eicocene copolymers, polyvinylpyrrolidone and hexadecene copolymers, nitrocellulose, dextrin fatty acid esters, and polymeric silicones. Examples of emollients include long-chain acylglutamic acid cholesteryl esters, hydroxystearate cholesteryl, 12-hydroxystearate, stearic acid, rosin acid, and lanolin fatty acid cholesteryl esters.

[0065] Examples of surfactants include nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants.

[0066] Examples of nonionic surfactants include self-emulsifying monostearate glycerin, propylene glycol fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, sorbitan fatty acid ester, POE (polyoxyethylene) sorbitan fatty acid ester, POE sorbitan fatty acid ester, POE glycerin fatty acid ester, POE alkyl ether, POE fatty acid ester, POE hydrogenated castor oil, POE castor oil, POE and POP (polyoxyethylene and polyoxypropylene) copolymer, POE and POP alkyl ether, polyether-modified silicone, alkanolamide lauric acid, alkylamine oxide, hydrogenated soybean phospholipid, etc.

[0067] Examples of anionic surfactants include fatty acid soaps, alpha-acylsulfonates, alkylsulfonates, alkylallylsulfonates, alkylnaphthalenesulfonates, alkyl sulfates, POE alkyl ether sulfates, alkylamide sulfates, alkyl phosphates, POE alkyl phosphates, alkylamide phosphates, alkylloylalkyl taurine salts, N-acyl amino acids, POE alkyl ether carboxylates, alkyl sulfosuccinates, sodium alkyl sulfoacetate, acylated hydrolyzed collagen peptide salts, perfluoroalkyl phosphate esters, etc.

[0068] Examples of cationic surfactants include alkyltrimethylammonium chloride, stearyltrimethylammonium chloride, stearyltrimethylammonium bromide, cetostearyltrimethylammonium chloride, distearyldimethylammonium chloride, stearyldimethylbenzylammonium chloride, behenyltrimethylammonium bromide, benzalkonium chloride, diethylaminoethylamide stearate, dimethylaminopropylamide stearate, and quaternary ammonium salts of lanolin derivatives. Examples of amphoteric surfactants include carboxybetaine type, amidebetaine type, sulfobetaine type, hydroxysulfobetaine type, amidesulfobetaine type, phosphobetaine type, aminocarboxylate type, imidazoline derivative type, amideamine type, etc.

[0069] Organic and inorganic pigments include inorganic pigments such as silica, anhydrous silica, magnesium silicate, talc, sericite, mica, kaolin, bengala, clay, bentonite, titanium-coated mica, bismuth oxychloride, zirconium oxide, magnesium oxide, zinc oxide, titanium oxide, aluminum oxide, calcium sulfate, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, iron oxide, ultramarine, chromium oxide, chromium hydroxide, calamine, and complexes thereof; Examples include polyamide, polyester, polypropylene, polystyrene, polyurethane, vinyl resin, urea resin, phenolic resin, fluoropolymer, silicone resin, acrylic resin, melamine resin, epoxy resin, polycarbonate resin, divinylbenzene and styrene copolymer, silk powder, cellulose, CI pigment yellow, CI pigment orange, and other organic pigments, as well as composite pigments of inorganic pigments and organic pigments.

[0070] As organic powders, metal soaps such as calcium stearate; metal alkyl phosphate salts such as sodium zinc cetylphosphate, zinc laurylphosphate, and calcium laurylphosphate; polyvalent metal salts of acyl amino acids such as calcium lauroyl-beta-alanine, zinc lauroyl-beta-alanine, and calcium lauroylglycine; polyvalent metal salts of amide sulfonic acids such as calcium lauroyl-taurine and calcium palmitoyl-taurine; N-acyl basic amino acids such as N-epsilon-lauroyl-L-lysine, N-epsilon-palmitoyllysine, N-alpha-palitoylolnitine, N-alpha-lauroyl arginine, and N-alpha-hydrogenated beef tallow fatty acid acyl arginine; and N-acyl polypeptides such as N-lauroylglycylglycine. Alpha-amino fatty acids such as alpha-aminocaprilic acid and alpha-aminolauric acid; polyethylene, polypropylene, nylon, polymethyl methacrylate, polystyrene, divinylbenzene and styrene copolymers, tetrafluoroethylene, etc. are examples.

[0071] As ultraviolet absorbers, para-aminobenzoic acid, ethyl para-aminobenzoate, amyl para-aminobenzoate, octyl para-aminobenzoate, ethylene glycol salicylate, phenyl salicylate, octyl salicylate, benzyl salicylate, butylphenyl salicylate, homomentyl salicylate, benzyl cinnamonate, paramethoxycinnamate-2-ethoxyethyl paramethoxycinnamate, octyl paramethoxycinnamate, mono-2-ethylhexaneglyceryl diparamethoxycinnamate, isopropyl paramethoxycinnamate, mixture of diisopropyl and diisopropyl cinnamonate esters, urocanic acid, ethyl urocanicate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenonesulfonic acid and its salts, dihydroxymethoxybenzophenone, sodium dihydroxymethoxybenzophenonedisulfonate, dihydroxybenzophenone, tetrahydroxybenzophenone, Examples include 4-tert-butyl-4'-methoxydibenzoylmethane, 2,4,6-trianilino-p-(carbo-2'-ethylhexyl-1'-oxy)-1,3,5-triazine, 2-(2-hydroxy-5-methylphenyl)benzotriazole, etc.

[0072] Examples of disinfectants include hinokitiol, triclosan, trichlorohydroxydiphenyl ether, chlorhexidine gluconate, phenoxyethanol, resorcinol, isopropylmethylphenol, azulene, salicylic acid, zincphyllithion, benzalkonium chloride, photosensitive element 301, mononitroguaiacol sodium, undecylenic acid, etc.

[0073] Examples of antioxidants include butylhydroxyanisole, propyl gallic acid, and elisorbic acid.

[0074] Examples of pH adjusters include citric acid, sodium citrate, malic acid, sodium malate, fumaric acid, sodium fumarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogen phosphate, etc.

[0075] Examples of alcohols include higher alcohols such as cetyl alcohol.

[0076] In addition, the ingredients that may be added are not limited to those mentioned above, and any of the above ingredients may be incorporated within a range that does not impair the purpose and effects of the present invention.

[0077] The cosmetic composition of the present invention may take the form of a solution, an emulsion, a viscous mixture, etc.

[0078] The ingredients included in the cosmetic composition of the present invention may include ingredients commonly used in cosmetic compositions as active ingredients, and include, for example, conventional auxiliary agents and carriers such as stabilizers, solubilizers, vitamins, pigments, and fragrances.

[0079] The cosmetic composition for skin whitening and anti-aging of the present invention can be prepared in any formulation commonly manufactured in the art, such as a lotion, cream, lotion, pack, foundation, lotion, beauty serum, hair cosmetic, etc.

[0080] Specifically, the cosmetic composition of the present invention includes formulations of skin lotion, skin softener, skin toner, milk lotion, astringent, lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, essence, nourishing essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, hair lotion, hair tonic, hair essence, hair shampoo, hair rinse, hair treatment, body lotion, and body cleanser.

[0081] In the case where the formulation of the present invention is a paste, cream, or gel, animal fibers, plant fibers, wax, paraffin, starch, tracanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as carrier components.

[0082] In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0083] In the case where the formulation of the present invention is a solution or emulsion, a solvent, a solvating agent, or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan.

[0084] In the case where the formulation of the present invention is a suspension, liquid diluents such as water, ethanol, or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used as carrier components.

[0085] In the case where the formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolin derivative, or ethoxylated glycerol fatty acid ester, etc. may be used as a carrier component.

[0087] In one aspect, the present invention provides a pharmaceutical composition for preventing or treating diseases caused by oxidative stress or inflammatory diseases, comprising a fermented cabbage extract as an active ingredient.

[0088] In one embodiment of the present invention, the disease caused by oxidative stress may be one or more selected from the group consisting of arteriosclerosis, heart failure, hypertensive heart disease, arrhythmia, myocardial infarction, hyperlipidemia, skin aging, immune disease and cancer, but is not limited thereto.

[0089] In one embodiment of the present invention, the inflammatory disease may be one or more selected from the group consisting of inflammatory bowel disease, inflammatory collagen vascular disease, glomerulonephritis, inflammatory skin disease, sarcoidosis, retinitis, gastritis, hepatitis, enteritis, arthritis, tonsillitis, pharyngitis, bronchitis, pneumonia, pancreatitis, sepsis, cystitis, nephritis, and neuritis, but is not limited thereto.

[0090] The pharmaceutical composition of the present invention may additionally include an adjuvant in addition to the fermented cabbage product. Any adjuvant known in the art may be used without limitation, but, for example, Freund's complete or incomplete adjuvant may be further included to increase immunity.

[0091] The pharmaceutical composition according to the present invention may be prepared in the form of incorporating a fermented cabbage product into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients, and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention are not limited to these, but may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0092] The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external formulations, suppositories, or sterile injectable solutions, each according to conventional methods.

[0093] When formulating, the product may be prepared using diluents or excipients such as commonly used fillers, volume expanders, binders, wetting agents, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and such solid dosage forms may be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., with the active ingredient. In addition, lubricants such as magnesium stearate and talc may also be used in addition to simple excipients. Liquid dosage forms for oral administration include suspensions, liquid formulations, emulsions, and syrups, and may contain various excipients, such as wetting agents, sweeteners, flavoring agents, and preservatives, in addition to commonly used diluents such as water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, water-insoluble solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Water-insoluble solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Bases for suppositories may include Witepsol, Tween 61, cocoa paste, laurin paste, glycerogelatin, etc.

[0094] The pharmaceutical composition according to the present invention may be administered to an individual by various routes. Any mode of administration may be anticipated, for example, by oral, intravenous, intramuscular, subcutaneous, or intraperitoneal injection.

[0095] The dosage of the pharmaceutical composition according to the present invention is selected by taking into consideration the age, weight, gender, physical condition, etc. of the individual. It is obvious that the concentration of the fermented cabbage included in the pharmaceutical composition can be selected in various ways depending on the target, and preferably, it is included in the pharmaceutical composition at a concentration of 0.01 to 5,000 μg / ml. If the concentration is less than 0.01 μg / ml, pharmaceutical activity may not appear, and if it exceeds 5,000 μg / ml, it may exhibit toxicity to the human body.

[0096] The above pharmaceutical composition can be formulated into various oral or parenteral administration forms.

[0097] Formulations for oral administration include, for example, tablets, pills, hard and soft capsules, liquids, suspensions, emulsifiers, syrups, granules, etc., and these formulations may additionally contain diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine) and lubricants (e.g., silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycol) in addition to fermented cabbage. Furthermore, the tablets may contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine, and in some cases may contain disintegrants or boiling mixtures such as starch, agar, alginic acid or its sodium salt and / or absorbents, coloring agents, flavoring agents and sweeteners. The above formulation can be prepared by conventional mixing, granulation, or coating methods.

[0098] In addition, representative formulations for parenteral administration are injectable preparations, and solvents for injectable preparations include water, Ringer's solution, isotonic saline, or suspensions. The sterile fixation oil of the above injectable preparation can be used as a solvent or suspension medium, and any non-irritating fixation oil, including mono- and di-glycerides, can be used for this purpose.

[0099] In addition, the above-mentioned injectable formulation may use fatty acids such as oleic acid.

[0101] As described above, specific embodiments of the present invention have been described in detail; however, those skilled in the art who understand the spirit of the present invention will be able to easily propose other inventions that are inferior or other embodiments included within the scope of the spirit of the present invention by adding, changing, or deleting other components within the same spirit. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention is defined by the claims set forth below rather than by the detailed description above, and all modifications or variations derived from the meaning and scope of the claims and equivalent concepts should be interpreted as being included within the scope of the present invention.

[0103] <Preparation Example 1> Preparation of Yeast Strain and Cabbage Powder Samples

[0104] 1-1. Yeast Strains and Culture Conditions

[0105] The yeast strain used in the present invention is Yarowia repolitica ( Yarrowia lipolytica )(Microorganism Accession No.: ATCC 18942), Devariomyces hanseni( Debaryomyces hansenii )(Microorganism Accession No.: ATCC 36239), Hanseniaspora uvalum( Hanseniaspora uvarum SRK0183)(Microorganism Accession No.: KCTC 15386BP), Peachia cluyberry( Pichia kluyveri SRK0727)(Microorganism Accession No.: KCTC 15385BP), Wicker's Hamomyces anomalus( Wickerhamomyces anomalus SRK0444)(Microorganism Accession No.: KCTC 15387BP), Saccharomyces boulardii( Saccharomyces boulardii )(Microorganism Accession No.: ATCC MYA-796), Cluiberomyces maxianus( Kluyveromyces marxianus )(Microorganism Accession No.: KCTC 17694), Saccharomyces cerevisiae( Saccharomyces cerevisiaeEight types of yeast strains from EC-1118 (purchased from: LALVIN, Canada) were used. H. uvarum , P. kluyveri , W. anomalus The three strains used were strains isolated and identified from peaches. Single colonies were plated on YPD (1% yeast extract, 2% peptone, 2% glucose) agar medium and cultured at 30°C for 48 hours, then inoculated into YPD broth medium. These were mass-cultured at 30°C at 250 rpm for 24 hours and used.

[0107] 1-2. Preparation of Cabbage Powder Samples

[0108] Cabbage used in the present invention ( Brassica oleracea var. capitata The cabbage was cut into appropriate sizes, washed, and dried at 60°C for 3 days. The dried cabbage was ground to prepare a cabbage powder sample, which was stored at -80°C for use. The moisture content of the cabbage powder was 14.8%, measured by the atmospheric pressure heating and drying method.

[0110] <Examples 1-1 to 1-8> Preparation of Fermented Cabbage Product

[0111] A 10% (w / w) cabbage powder solution was prepared by mixing distilled water with the cabbage powder sample prepared in Preparation Example 1-2 above, and then subjected to hot water treatment at 121°C for 15 minutes. After inoculating each of the eight types of yeast cells mass-cultured in Preparation Example 1-1 above at an initial cell concentration of 0.5 g / L, the samples were fermented for 24 hours at 30°C under conditions of 250 rpm to produce the fermented cabbage products of Examples 1-1 to 1-8.

[0113] Types of cabbage fermentation yeast Example 1-1 Yarrowia lipolytica (YL) Examples 1-2 Debaryomyces hansenii (DH) Examples 1-3 Hanseniaspora uvarum (HU) Examples 1-4 Pichia kluyveri (PK) Examples 1-5 Wickerhamomyces anomalus (WA) Examples 1-6 Saccharomyces boulardii (SB) Examples 1-7 Kluyveromyces marxianus (KM) Examples 1-8 Saccharomyces cerevisiae (SC)

[0115] <Comparative Example 1> Preparation of Broccoli Puree

[0116] To prepare broccoli puree, broccoli was cut into pieces about 2 cm in size and mixed with Milli-Q water in a ratio of 3:2. This was homogenized using a blender for 1 minute, then portioned into sterile containers for use.

[0118] <Comparative Example 2> Preparation of fermented broccoli

[0119] 2-1. Preparation of Starter Culture

[0120] For broccoli fermentation, separated from broccoli Leuconostoc mesenteroides (BF1, BF2) and Lactobacillus plantarum (B1, B2, B3, B4, B5) were cultured in MRS liquid medium at 30°C for 24 hours. After culture, the culture obtained by centrifuging at 3500 g at 4°C for 15 minutes was washed twice with Phosphate buffer saline (PBS). After washing, the culture was suspended in Milli-Q water to a concentration of 10 log CFU / mL. L. plantarum culture solution and Leu. mesenteroides The culture solution was mixed in a 1:1 volume ratio and stored at -80 ℃ with glycerol for use.

[0122] 2-2. Preparation of Fermented Broccoli

[0123] 200 mL of broccoli puree prepared in Comparative Example 1 was inoculated with 8 log CFU / mL of starter culture and cultured. After 4 days of culture, fermentation was carried out at 30 ℃ until the pH reached ~4.0.

[0125] <Experimental Example 1> Measurement of Survival Rate of 8 Types of Yeast

[0126] The yeast survival rate of the cabbage fermentation product prepared in Example 1 above was measured and is shown in Figure 1.

[0127] As shown in Figure 1, when cabbage powder solutions were fermented for 24 hours using eight types of yeast, the yeast survival rate after 24 hours of fermentation was expressed as a log value compared to before fermentation. The results showed an increase of 8.7% for Example 1-1, 21.2% for Example 1-2, 1.9% for Example 1-3, 34.2% for Example 1-4, 14.8% for Example 1-5, 13.7% for Example 1-6, 12.8% for Example 1-7, and 13.3% for Example 1-8. Among these, Examples 1-4 and 1-8 showed a significant increase (p < 0.05).

[0128] Through this, it was confirmed that fermentation is possible in a hot water-treated cabbage powder solution.

[0130] <Experimental Example 2> Measurement of pH, water-soluble solid content (°BX), and viable cell count of fermented cabbage

[0131] 0.5 mL of cabbage powder solution before and after fermentation was placed in 1.5 mL of each, and the pH of the cabbage powder was measured using a pH meter (SevenCompact pH meter S220, Mettler Toledo, Columbus, OH, USA).

[0132] The cabbage powder solution before and after fermentation was centrifuged at 13,000 rpm for 10 minutes, and 0.3 mL of the supernatant was measured using a Hand refractometer (Atago Pocket Pal-1, Atago Co. Ltd., Tokyo, Japan) to determine the water-soluble solid content of the cabbage powder.

[0133] The fermented cabbage powder solution was serially diluted and plated on YPD agar medium. The colonies formed were incubated at 30°C for 24 hours, and the viable cell count was measured by converting the result to CFU / mL.

[0134] The measured pH, water-soluble solid content, and viable cell count are shown in Table 2 and Figure 2 below.

[0136] pH soluble solids(°BX) Log N / N 0 10% cabbage powder solution 5.01 ± 0.02 8.43 ± 0.35 - Example 1-1 5.19 ± 0.06 8.10 ± 0.10 0.50 Examples 1-2 4.72 ± 0.04 7.73 ± 0.06 1.32 Examples 1-3 4.65 ± 0.00 6.63 ± 0.06 0.14 Examples 1-4 4.63 ± 0.09 5.23 ± 0.06 2.14 Examples 1-5 4.28 ± 0.03 5.13 ± 0.21 1.08 Examples 1-6 4.34 ± 0.04 5.07 ± 0.06 0.96 Examples 1-7 4.44 ± 0.04 4.97 ± 0.06 0.90 Examples 1-8 4.51 ± 0.10 4.83 ± 0.21 0.94

[0137] N: Number of living cells after 24 hours of fermentation

[0138] N0: Number of living cells before fermentation

[0139] Log N / N0: Change in viable cell count

[0141] As shown in Table 2 and Figure 2, after cabbage fermentation, all yeasts except Example 1-1 showed a tendency for water-soluble solid content and pH to decrease, and the pH tended to decrease as the water-soluble solid content decreased. The number of viable cells increased with fermentation, but there was no correlation between the degree of increase in the number of viable cells and the degree of decrease in water-soluble solid content.

[0142] Through this, it was confirmed that all 8 types of yeast effectively fermented the water-soluble solids of cabbage, reducing the content of water-soluble solids and pH.

[0144] <Experimental Example 3> Measurement of Free Sugar Consumption in Fermented Cabbage

[0145] To confirm the extent of substrate consumption and metabolite production by yeast, the concentrations of glucose, fructose, glycerol, acetate, and ethanol in the fermented 10% cabbage powder solution were determined using Rezex-ROA Organic Acid H + The samples were analyzed using a high-performance liquid chromatography (HPLC 1260 series, Agilent Technologies, Santa Clara, CA, USA) equipped with a column (8%, 150 mm × 4.6 mm; Phenomenex Inc., Torrance, CA, USA). The samples were eluted with 0.005 N H2SO4 at 0.6 mL / min and 50 °C and analyzed, with the results shown in Table 3 and Figure 3 below. Figure 3(i) shows the fermentation of Examples 1-8 diluted 10-fold.

[0147] Metabolities (g / L) Glucose Fructose Glycerol Acetate Ethanol Example 1-1 15.73 ± 0.38 17.00 ± 0.04 - - - Examples 1-2 16.44 ± 1.15 17.42 ± 0.08 0.68 ± 0.02 0.40 ± 0.03 1.78 ± 0.19 Examples 1-3 5.22 ± 0.10 - 1.62 ± 0.07 0.88 ± 0.06 9.19 ± 0.10 Examples 1-4 2.91 ± 0.39 - 0.93 ± 0.14 - 10.35 ± 1.52 Examples 1-5 0.42 ± 0.73 - 0.41 ± 0.42 1.35 ± 0.16 12.60 ± 1.98 Examples 1-6 - - 1.96 ± 0.08 1.46 ± 0.21 15.75 ± 1.77 Examples 1-7 0.37 ± 0.05 - 2.29 ± 0.07 1.03 ± 0.16 15.21 ± 1.46 Examples 1-8 0.29 ± 0.12 - 2.04 ± 1.04 1.10 ± 1.50 17.82 ± 1.96

[0149] Table 3 shows the free sugars and metabolites after 24 hours of fermentation. As shown in Table 3 and Figure 3, approximately 36% (w / v) of the free sugars in the 10% cabbage powder solution were present as glucose and fructose. Examples 1-1 and 1-2 consumed almost no cabbage free sugars and did not produce any metabolites. Examples 1-3 and 1-4 consumed all the fructose within 12 hours but did not consume all the glucose. The maximum ethanol production of Example 1-3 was approximately 10.8 g / L, and that of Example 1-4 was approximately 13.5 g / L. Example 1-5 consumed all the glucose and fructose within 18 hours of fermentation and produced approximately 14.2 g / L of ethanol. Examples 1-6, 1-7, and 1-8 consumed all glucose and fructose within 12 hours of fermentation and produced 17.8 g / L, 17.3 g / L, and 20.1 g / L of ethanol, respectively. Even when fermentation was performed with the concentration of Example 1-8 diluted 10-fold (Fig. 3 (i)), all sugars were consumed within 12 hours of fermentation and approximately 18.6 g / L of ethanol was produced.

[0150] Through this, the strains that effectively fermented using glucose and fructose, which are free sugars of cabbage, are Examples 1-5, 1-6, 1-7, and 1-8. Among them, since Example 1-8, which was diluted 10 times, effectively fermented using glucose and fructose, it was confirmed that Example 1-8 is effective for the fermentation of water-soluble solids of cabbage.

[0152] <Experimental Example 4> Measurement of Sulforaphane Production in Fermented Cabbage

[0153] Cabbage is a vegetable that helps reduce the risk of cardiovascular disease and cancer, and glucoraphanin and sulforaphane, breakdown products of glucosinolates, are attributed to these health benefits. Glucoraphanin is spontaneously converted into sulforaphane by myrosinase when tissue damage occurs in the vegetable.

[0154] To a 10% cabbage powder solution sterilized at 121°C for 15 minutes S. cerevisiae and S. boulardii Each was inoculated and fermented for 12 hours at 30°C under conditions of 250 rpm. The fermented cabbage powder solution was freeze-dried to powder. 5 g of the cabbage powder sample, 50 mL of dichloromethane, and 2.5 g of anhydrous sodium sulfate were mixed and ultrasonically extracted at 30°C for 5 minutes, followed by centrifugation to obtain the supernatant. The pellet was rehydrated in 50 mL of dichloromethane, and extraction was performed once more. Both the first and second supernatants were vacuum filtered and dehydrated at 30°C using a rotary evaporator. The residue was dissolved in 4 mL of acetonitrile and filtered through a 0.2 μm syringe filter. Sulforaphane was analyzed by high-performance liquid chromatography (HPLC) using a 2996 photodiode array detector (Waters, Alliance 2796 Separation System) connected to a Kinetex C18 100A column (5 μm, 250 mm x 4.6 mm: Phenomenex Inc.). A 205 nm wavelength UV / Vis spectrophotometer (Optizen NanoQ, Mecasys Co., Daejae, Korea) was used for sulforaphane detection. The sulforaphane detection results are shown in Table 4 below.

[0156] Sulforaphane content Cabbage (control group) 0.25 ± 0.10 mg / 100 g powder Examples 1-6 1.59 ± 0.66 mg / 100 g powder Examples 1-8 1.40 ± 0.41 mg / 100 g powder Comparative Example 1 0.48 μg / 100 g dry weight Comparative Example 2 0.91 μg / 100 g dry weight

[0158] As shown in Table 4, the sulforaphane content of Examples 1-6 and 1-8 increased by 5.6 times and 6.4 times, respectively, compared to the control group, while Comparative Example 2 increased by more than 1.9 times compared to Comparative Example 1. Through this, compared to the sulforaphane increase rate of broccoli fermented with lactic acid bacteria (Comparative Example 2), Saccharomyces boulardii or Saccharomyces cerevisiae It was confirmed that the sulforaphane increase rate of cabbage fermented with (Examples 1-6 or 1-8) was superior.

[0159] Previous studies have shown that cabbage fermentation using lactic acid bacteria aids in the conversion of glucoraphanin into sulforaphane and increases the sulforaphane content after fermentation. As such, compared to the control group, Saccharomyces boulardii or Saccharomyces cerevisiae Since the sulforaphane content of cabbage fermented with (Example 1-6 or Example 1-8) increased, this means that glucoraphanin was converted into sulforaphane.

[0161] <Experimental Example 5> Measurement of cytotoxicity of fermented cabbage

[0162] 5-1. Sample Preparation

[0163] To analyze the functionality of the fermented cabbage product at the in vitro and cellular levels, the yeast that most rapidly fermented the free sugars of cabbage, glucose and fructose, in Experimental Example 3 was used. S. cerevisiae and S. boulardii We selected and proceeded with the analysis.

[0164] Fermentation was carried out in the same manner as in Example 1, and since all sugars were consumed within 12 hours, the fermentation time was shortened to 12 hours. The sample was prepared by centrifuging the fermented cabbage product to obtain the supernatant, and then freeze-drying it. The control group was prepared by centrifuging an unfermented 10% cabbage solution to obtain the supernatant, and then freeze-drying it.

[0166] 5-2. Cell Culture

[0167] The mouse macrophage RAW 264.7 cell line was purchased from the Korean Cell Line Bank (Korean Cell Line Research Foundation, Seoul, Republic of Korea). RAW 264.7 cells were cultured in DMEM medium supplemented with 10% FBS and 1% penicillin in a 5% CO2 humidified atmosphere incubator at 37 ℃. When cell confluency reached 80–90%, subculture was performed at 2 x 10⁶ 5 It was performed at cells / mL, and the above process was repeated every 2 days.

[0169] 5-3. Measurement of Cytotoxicity of Fermented Cabbage

[0170] Cabbage fermentation product diluted in the medium to a concentration of 5 µg / mL was added to RAW 264.7 macrophages and cultured for 24 hours. After culture, 10 µl of thiazolyl blue (MTT) reagent was added. After 2 hours, 80 µl was removed from the cell culture medium, and 100 µl of DMSO was added and mixed at 100 rpm for 30 minutes under dark conditions. After mixing, the absorbance was measured at 595 nm using a microplate reader (Bio-Rad Inc., Hercules, CA, USA) and is shown in Figure 4.

[0171] As shown in Figure 4, it was confirmed that there was no decrease in the viability of RAW 264.7 macrophages cultured in Examples 1-6 or 1-8 compared to the control group.

[0172] Through this, a concentration of 5 µg / mL S. cerevisiae and S. boulardiiIt was confirmed that the cabbage fermentation solution (Examples 1-6 and 1-8) fermented with [the agent] had no cytotoxicity in RAW 264.7 macrophages. Therefore, the antioxidant activity and anti-inflammatory effects were measured at a concentration of 5 μg / mL in Examples 1-6 or 1-8.

[0174] <Experimental Example 6> Measurement of Antioxidant Activity Effect of Fermented Cabbage

[0175] 6-1. Confirmation of Free Radical Scavenging Activity

[0176] To confirm free radical scavenging activity, an ABTS radical scavenging activity test was performed. ABTS (2,2-azompbos-(3-ethylbenzothiazoline-sulfonic acid)) radical scavenging activity was determined by reacting 100 µl of fermented cabbage dissolved in sterilized PBS with 100 µl of 437.5 nM ABTS reagent for 30 minutes under dark conditions, and then measuring the absorbance at 595 nm. The ABTS radical scavenging activity was calculated as a percentage using the following Equation 1. The measured ABTS radical scavenging activity is shown in Figure 5.

[0178]

[0180] As shown in Figure 5, ABTS radical scavenging activity of over 10% was confirmed in Examples 1-6 and 1-8, which is a value similar to that of the positive control, Ascorbic acid 1 μg / mL.

[0181] Through this, Saccharomyces cerevisiae (SC) and Saccharomyces boulardii The ABTS radical scavenging activity of cabbage fermented with (SB) (Examples 1-6 and 1-8) was confirmed, which means that the fermented cabbage has excellent antioxidant activity.

[0183] 6-2. Confirmation of ROS generation inhibitory efficacy

[0184] To determine the effect of cabbage fermentation on ROS production, RAW 264.7 cells were 3 x 10 5Cells were cultured in 96-well plates at a density of 200 µg per cell / mL for 1 day. The fermented cabbage extract was diluted to a concentration of 5 µg / mL in the medium and treated, followed by the addition of 1 µg / mL of LPS 1 hour later. After 24 hours, the cells were washed twice with sterilized PBS. To measure intracellular ROS generation, 200 µl of the fluorescent substance DCFH-DA, diluted to 20 µM in phenol-free DMEM, was added to the cells, and the cells were incubated in the dark. After 30 minutes, the cells were washed twice with sterilized PBS, and fluorescence measurements were taken using a Leica-Microsystems (Wetzlar, Germany). Image analysis was performed using MetaMorphsoftware (Molecular Devices, Danville, PA, USA). The measured ROS generation inhibitory efficacy is shown in Figure 6.

[0185] As shown in Figure 6, compared to the control group, the amount of ROS generated in Examples 1-8 decreased by 26.05% and in Examples 1-6 by 34.91%, confirming that ROS generation was reduced in Examples 1-6 and 1-8.

[0186] Through this, Saccharomyces cerevisiae (SC) and Saccharomyces boulardii It was confirmed that cabbage fermented with (SB) (Examples 1-6 and 1-8) inhibits ROS production and has excellent antioxidant activity.

[0188] <Experimental Example 7> Measurement of Anti-inflammatory Activity of Fermented Cabbage

[0189] 7-1. Confirmation of Nitrite Production Inhibitory Efficacy

[0190] To determine the effect of cabbage fermentation on nitrite production, RAW 264.7 cells were 3 x 10 5Cells were cultured in 96-well plates at a density of 200 µl per well for 1 day. The cabbage fermentation product was diluted in the medium to a concentration of 5 µg / mL, and 1 µg / mL of LPS was added after 1 hour. After 24 hours, 100 µl of a 1:1 mixture of Griess reagent A (1% 4-aminobenzenesulfonamide, 0.2% N1-(naphthalenl-yl)ethane-1,2-diamine dihydrochloride) and Griess reagent B (5% phosphoric acid) was added to 100 µl of the cell culture medium, and the mixture was reacted at 100 rpm for 30 minutes. Absorbance was measured at 550 nm using a microplate reader, and the measured absorbance is shown in Figure 7.

[0191] As shown in Figure 7, compared to the control group, the amount of nitrite produced in Examples 1-8 decreased by 2.22% and in Examples 1-6 decreased by 14.67%, confirming that nitrite production was suppressed in Examples 1-6 and 1-8.

[0192] Through this, Saccharomyces cerevisiae (SC) and Saccharomyces boulardii It was confirmed that cabbage fermented with (SB) (Examples 1-6 and 1-8) inhibited nitrite production and exhibited excellent anti-inflammatory activity.

[0194] 7-2. Confirmation of iNOS protein expression inhibitory efficacy

[0195] To confirm the expression of iNOS protein, an enzyme that produces nitrite, a protein aspiration method was performed. RAW 264.7 cells (3 x 10 5Cells (cells / mL) were cultured in 6 cm plates for 1 day. After cell confluency reached 50–60%, 5 µg / mL of fermented cabbage extract was added to the cells, followed by the addition of 1 µg / mL of LPS 1 hour later, and the cells were cultured for 24 hours. Intracellular proteins were obtained by adding 100 µl of lysis buffer (Cell Signaling Technologies, Danvers, MA, USA) containing a phosphatase inhibitor cocktail and protease (Thermo Fisher Scientific Inc., Waltham, UT, USA), and were separated using an SDS-PAGE gel. Subsequently, the transferred membranes were blocked using TBS-T buffer containing 5% skim milk, and after 1 hour, iNOS, COX-2 (cell signaling) antibodies and β-actin (Santa Cruz) antibodies were reacted overnight at 4°C. Afterwards, a secondary antibody was reacted with the membrane, and the level of protein expression was measured using EzWest Lumi plus (ATTO, Tokyo, Japan) and is shown in Figure 8.

[0196] As shown in Figure 8, it was confirmed that iNOS protein expression decreased in Examples 1-8.

[0197] Since the production of nitrite is reduced through the decrease in iNOS protein, this Saccharomyces cerevisiae This means that cabbage fermented with (SC) (Examples 1-8) has excellent anti-inflammatory activity.

[0199] Based on these results, a 10% (w / w) cabbage powder solution was fermented with 8 types of yeast, and Saccharomyces cerevisiae It was confirmed that the fermented cabbage product (Examples 1-8) produced through fermentation showed significantly superior effects in sulforaphane production, antioxidant activity, and anti-inflammatory enhancement.

[0201] The present invention has been described above with reference to preferred embodiments and experimental examples. Those skilled in the art will understand that the present invention may be embodied in modified forms without departing from the essential characteristics of the invention. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the invention is defined by the claims, not by the foregoing description, and all variations within the scope of the claims should be interpreted as being included in the invention.

Claims

Claim 1 Saccharomyces cerevisiae Saccharomyces cerevisiae A health functional food composition for antioxidant or anti-inflammatory purposes, comprising as an active ingredient a fermented cabbage (Brassica oleracea var. capitata) product fermented with ), wherein the fermented cabbage product is prepared by mixing cabbage and distilled water in a weight ratio of 1:7 to 13 and fermenting the mixture, wherein the fermentation is performed at 15 to 45 ℃ at 200 to 300 rpm for 20 to 28 hours, wherein the fermented cabbage product promotes the production of sulforaphane, wherein the fermented cabbage product inhibits the production of nitrite, and wherein the fermented cabbage product inhibits the activity of inducible nitric oxide synthetase (iNOS). Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 delete Claim 7 delete Claim 8 delete Claim 9 Saccharomyces cerevisiae Saccharomyces cerevisiae Cabbage fermented with ) Brassica oleracea var. capitata A cosmetic composition for antioxidant or anti-inflammatory purposes comprising a fermented product as an active ingredient, wherein the cabbage fermented product is prepared by mixing cabbage and distilled water in a weight ratio of 1:7 to 13 and fermenting the mixture, wherein the fermentation is performed at 15 to 45 ℃ at 200 to 300 rpm for 20 to 28 hours, wherein the cabbage fermented product promotes the production of sulforaphane, wherein the cabbage fermented product inhibits the production of nitrite, and wherein the cabbage fermented product inhibits the activity of inducible nitric oxide synthetase (iNOS). Claim 10 delete Claim 11 delete Claim 12 delete

Citation Information

Patent Citations

  • Cosmetic composition comprising the mixed extracts of achillea, borage, helichrysum, lady's mantle, and eucalyptus

    KR1020130066466A